Terrance P. Snutch
Corporate Officer/Principal en University of British Columbia .
Cargos activos de Terrance P. Snutch
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
University of British Columbia | Corporate Officer/Principal | - | - |
Historial de carrera de Terrance P. Snutch
Antiguos cargos conocidos de Terrance P. Snutch.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
CombinatoRx, Inc.
CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | Director Técnico/Científico/I+D | 22/12/2009 | 10/09/2010 |
Neuromed Pharmaceuticals Ltd.
Neuromed Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Neuromed Pharmaceuticals Ltd. develops chronic pain drugs. Its NMED-1077 product is an extended release formulation of hydromorphone in phase 3 clinical development. It conducts research for drugs to cure anxiety, epilepsy, hypertension, and cardiovascular diseases. The company was founded by Dr. Terrance P. Snutch in 1998 and is headquartered in Vancouver, BC. | Director Técnico/Científico/I+D | 01/01/1998 | 27/01/2010 |
Fundador | 28/12/2009 | 27/01/2010 | |
Neuromed Pharmaceuticals, Inc.
Neuromed Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Neuromed Pharmaceuticals, Inc. develops new and improved pain medicines. It has multiple programs aimed at addressing this important unmet medical need. Its lead product candidate, ExalgoTM is an extended release formulation of hydromorphone in phase 3 clinical development. Neuromed is also developing oral drug candidates to block N-type and T-type calcium channels, an important target directly involved in pain signaling, and includes candidates for potentially treating pain, epilepsy and hypertension. | Director Técnico/Científico/I+D | - | 27/01/2010 |
Formación de Terrance P. Snutch.
Simon Fraser University | Doctorate Degree |
Estadísticas
Internacional
Canadá | 4 |
Estados Unidos | 3 |
Operativa
Chief Tech/Sci/R&D Officer | 3 |
Founder | 1 |
Doctorate Degree | 1 |
Sectorial
Health Technology | 4 |
Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 3 |
---|---|
Neuromed Pharmaceuticals Ltd.
Neuromed Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Neuromed Pharmaceuticals Ltd. develops chronic pain drugs. Its NMED-1077 product is an extended release formulation of hydromorphone in phase 3 clinical development. It conducts research for drugs to cure anxiety, epilepsy, hypertension, and cardiovascular diseases. The company was founded by Dr. Terrance P. Snutch in 1998 and is headquartered in Vancouver, BC. | Health Technology |
Neuromed Pharmaceuticals, Inc.
Neuromed Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Neuromed Pharmaceuticals, Inc. develops new and improved pain medicines. It has multiple programs aimed at addressing this important unmet medical need. Its lead product candidate, ExalgoTM is an extended release formulation of hydromorphone in phase 3 clinical development. Neuromed is also developing oral drug candidates to block N-type and T-type calcium channels, an important target directly involved in pain signaling, and includes candidates for potentially treating pain, epilepsy and hypertension. | Health Technology |
CombinatoRx, Inc.
CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | Health Technology |
- Bolsa de valores
- Insiders
- Terrance P. Snutch
- Experiencia